China has approved an early-stage trial in humans of German firm BioNTech’s (22UAy.F) (BNTX.O) experimental COVID-19 vaccine, its local partner Shanghai Fosun Pharmaceutical (600196.SS) (2196.HK) said on Thursday.
The potential vaccine is one of the two most advanced candidates that BioNTech is working on with its partner Pfizer Inc (PFE.N) and they received “fast track” status this week from the U.S. Food and Drug Administration which is designed to speed up the regulatory review process.
Fosun Pharma said in a filing that a unit will initiate a Phase I clinical trial of BNT162b1 “as soon as possible once it is ready”.
It is licensed to exclusively develop and commercialize COVID-19 vaccine products developed by using BioNTech’s mRNA technology in mainland China, Hong Kong, Macau and Taiwan.
I run this site in my spare time and thoroughly enjoy giving you all positive news! If you’ve enjoyed the site we’d love for you to help me share the good news far and wide, share us on Reddit, your Facebook or your Twitter and spread a little positivity around.